We are live on ! Find out more
FLSM

Frazier Life Sciences Management Portfolio holdings

AUM $3.89B
1-Year Est. Return 201.1%
This Fund
S&P 500
This Quarter Est. Return
-1.92%
1 Year Est. Return
+201.1%
3 Year Est. Return
+879.31%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.38B
AUM Growth
-$227M
Cap. Flow
-$69M
Cap. Flow %
-4.99%
Top 10 Hldgs %
65.28%
Holding
52
New
8
Increased
7
Reduced
4
Closed
3

Top Buys

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$21M
2
ELVN icon
Enliven Therapeutics
ELVN
+$16.9M
3
BBIO icon
BridgeBio Pharma
BBIO
+$13.7M
4
MGNX icon
MacroGenics
MGNX
+$10.3M
5
THRX
Theseus Pharmaceuticals, Inc. Common Stock
THRX
+$8.34M

Top Sells

Rank Stock Value
1
IMGO
Imago BioSciences, Inc. Common stock
IMGO
+$143M
2
ALLK
Allakos
ALLK
+$23.5M
3
REPL icon
Replimune Group
REPL
+$5.82M
4
KRYS icon
Krystal Biotech
KRYS
+$4.27M
5
EPIX
ESSA Pharma
EPIX
+$1.52M

Sector Composition

Rank Sector Weight
1 Healthcare 99.93%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APTX
51
DELISTED
Aptinyx Inc. Common Stock
APTX
– –
-1,883,244
Closed -$537K
IMGO
52
DELISTED
Imago BioSciences, Inc. Common stock
IMGO
– –
-3,987,207
Closed -$143M
1 2
3

Similar funds

GAMH
Greenwoods Asset Management (HK) Hong Kong $3.88B AUM 23.82% 1-Year Est. Return
MSI
Mitsui Sumitomo Insurance Tokyo, Japan $3.9B AUM
CCM
Channing Capital Management Chicago, Illinois $3.91B AUM 34.32% 1-Year Est. Return
TFM
Trian Fund Management New York $3.86B AUM 26.59% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
MIM
Meridiem Investment Management London, United Kingdom $3.92B AUM 1.64% 1-Year Est. Return
AA
Alesco Advisors Pittsford, New York $3.92B AUM 15.21% 1-Year Est. Return
DACG
Donor Advised Charitable Giving San Francisco, California $3.92B AUM 59.92% 1-Year Est. Return

Frazier Life Sciences Management's Q1 2023 Portfolio in Review

As of Q1 2023, Frazier Life Sciences Management held 52 positions worth $1.38B, down 14% from $1.61B the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Frazier Life Sciences Management withdrew a net $69M in Q1 2023, closing 3 positions and reducing 4 holdings. Its most notable exit was Imago BioSciences, Inc. Common stock, an estimated $143M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier.

Against the trend, Frazier Life Sciences Management opened a new position in Revolution Medicines worth $18.5M.

  • Frazier Life Sciences Management's largest Q1 2023 buy was Revolution Medicines: 854,484 shares worth $18.5M.
  • Frazier Life Sciences Management added most to Theseus Pharmaceuticals, Inc. Common Stock in Q1 2023, an estimated $8.34M increase.
  • Frazier Life Sciences Management's biggest Q1 2023 reduction was Allakos, cutting an estimated $23.5M.
  • Frazier Life Sciences Management fully exited Imago BioSciences, Inc. Common stock in Q1 2023, selling an estimated $143M.
  • Frazier Life Sciences Management's ten largest holdings make up 65% of its $1.38B portfolio in Q1 2023.
  • Frazier Life Sciences Management opened 8 new positions and closed 3 in Q1 2023.
  • Frazier Life Sciences Management's portfolio value fell 14% quarter-over-quarter to $1.38B.

Based on Frazier Life Sciences Management's 13F filing for Q1 2023, filed 15 May 2023.